Cargando…
Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data
BACKGROUND AND OBJECTIVES: Patients with multiple sclerosis (MS) transition from oral sphingosine-1-receptor (S1P) modulators to anti-CD20 therapies for several circumstances. Optimal timing of this transition is uncertain, given competing concerns of rebound disease activity and ensuring immune rec...
Autores principales: | Rowles, William M., Hsu, Wan-Yu, McPolin, Kira, Li, Alyssa, Merrill, Steven, Guo, Chu-Yueh, Green, Ari J., Gelfand, Jeffrey Marc, Bove, Riley M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128034/ https://www.ncbi.nlm.nih.gov/pubmed/35581005 http://dx.doi.org/10.1212/NXI.0000000000001183 |
Ejemplares similares
-
Remote Observational Research for Multiple Sclerosis: A Natural Experiment
por: Bove, Riley, et al.
Publicado: (2022) -
CoachMS, an innovative closed-loop, interdisciplinary platform to monitor and proactively treat MS symptoms: A pilot study
por: Block, Valerie J, et al.
Publicado: (2021) -
Effects of melatonin on sleep disturbances in multiple sclerosis: A randomized, controlled pilot study
por: Hsu, Wan-Yu, et al.
Publicado: (2021) -
Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic
por: McGinley, Marisa P, et al.
Publicado: (2021) -
Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis
por: Morales-Rodriguez, Denisse, et al.
Publicado: (2023)